The efficacy of intravitreal aflibercept given in a ‘treat and extend’ regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion

Centre for Eye Research Australia0 个研究点目标入组 20 人开始时间: 2015年5月1日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•1. Age greater than or equal to18 years
•2. CRVO with cystoid macular as determined by fluorescein angiography and duration of onset less than 12 months
•3. Best-corrected visual acuity (BCVA) of 17-70 letters (6/12 –6/120)
•4. Central macular thickness of greater than or equal to 300 microns as measured by Heidelberg Optical coherence tomography.
•5. Absent relative afferent pupillary defect

•1. Uncontrolled blood pressure (greater than or equal to180 mmHg, systolic and 110 mmHg, diastolic)
•2. Chronic renal failure
•3. Major surgery within one month of study
•4. Previous systemic anti-VEGF treatment
•5. Women of childbearing potential not using adequate contraception and women who are breast feeding
•6. Intercurrent severe disease such as septicaemia
•1. Glaucoma which is uncontrolled with intraocular pressure-lowering medications
•2. Past history of severe steroid response with IOP greater than or equal to 35 mmHg following steroid treatment
•3. Loss of vision due to other causes (e.g. age-related macular degeneration, myopic macular degeneration)
•4. VA of <6/60 in the fellow eye
•5. Argon laser photocoagulation within 3 months of study entry
•6. Previous intraocular surgery (within 6 months)
•7. Stroke or myocardial infarction less than 3 months prior to screening.
•8. Any active periocular or ocular infection or inflammation at screening or baseline.
•9. Subjects, who in the opinion of the Investigator, may not benefit from the Investigational Product due to pre-existing or current macular condition (eg, vitreomacular traction, epiretinal membrane, scar, foveal atrophy)

发起方